4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1

Ann W. Kinyua, Chang Mann Ko, Khanh V. Doan, Dong Joo Yang, My Khanh Q. Huynh, Sang Hyun Moh, Yun Hee Choi, Ki Woo Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is known to have numerous beneficial health effects, including anti-obesity and anti-hyperglycemic properties. However, the molecular networks that modulate the beneficial FA-induced metabolic effects have not been well elucidated. In this study, we explored the molecular mechanisms mediating the beneficial metabolic effects of FA. In mice, FA protected against high-fat diet-induced weight gain, reduced food intake and exhibited an overall improved metabolic phenotype. The food intake suppression by FA was accompanied by a specific reduction in hypothalamic orexigenic neuropeptides, including agouti-related protein and neuropeptide Y, with no significant changes in the anorexigenic peptides pro-opiomelanocortin and cocaine and amphetamine-regulated transcript. FA treatment also inhibited fat accumulation in the liver and white adipose tissue and suppressed the expression of gluconeogenic genes, including phosphoenolpyruvate carboxylase and glucose-6-phosphatase. Furthermore, we show that FA phosphorylated and inactivated the transcription factor FoxO1, which positively regulates the expression of gluconeogenic and orexigenic genes, providing evidence that FA might exert its beneficial metabolic effects through inhibition of FoxO1 function in the periphery and the hypothalamus.

Original languageEnglish
Article numbere437
JournalExperimental and Molecular Medicine
Volume50
Issue number2
DOIs
Publication statusPublished - 2018 Feb 2

Fingerprint

ferulic acid
Phosphorylation
Homeostasis
Glucose
Peptides
Liver
Agouti-Related Protein
Eating
Genes
Fats
Phosphoenolpyruvate Carboxylase
Glucose-6-Phosphatase
Pro-Opiomelanocortin
White Adipose Tissue
Neuropeptide Y

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Kinyua, Ann W. ; Ko, Chang Mann ; Doan, Khanh V. ; Yang, Dong Joo ; Huynh, My Khanh Q. ; Moh, Sang Hyun ; Choi, Yun Hee ; Kim, Ki Woo. / 4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1. In: Experimental and Molecular Medicine. 2018 ; Vol. 50, No. 2.
@article{b50c104a6ffc43b9b66b4e810e573f4d,
title = "4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1",
abstract = "4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is known to have numerous beneficial health effects, including anti-obesity and anti-hyperglycemic properties. However, the molecular networks that modulate the beneficial FA-induced metabolic effects have not been well elucidated. In this study, we explored the molecular mechanisms mediating the beneficial metabolic effects of FA. In mice, FA protected against high-fat diet-induced weight gain, reduced food intake and exhibited an overall improved metabolic phenotype. The food intake suppression by FA was accompanied by a specific reduction in hypothalamic orexigenic neuropeptides, including agouti-related protein and neuropeptide Y, with no significant changes in the anorexigenic peptides pro-opiomelanocortin and cocaine and amphetamine-regulated transcript. FA treatment also inhibited fat accumulation in the liver and white adipose tissue and suppressed the expression of gluconeogenic genes, including phosphoenolpyruvate carboxylase and glucose-6-phosphatase. Furthermore, we show that FA phosphorylated and inactivated the transcription factor FoxO1, which positively regulates the expression of gluconeogenic and orexigenic genes, providing evidence that FA might exert its beneficial metabolic effects through inhibition of FoxO1 function in the periphery and the hypothalamus.",
author = "Kinyua, {Ann W.} and Ko, {Chang Mann} and Doan, {Khanh V.} and Yang, {Dong Joo} and Huynh, {My Khanh Q.} and Moh, {Sang Hyun} and Choi, {Yun Hee} and Kim, {Ki Woo}",
year = "2018",
month = "2",
day = "2",
doi = "10.1038/emm.2017.253",
language = "English",
volume = "50",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "2",

}

4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1. / Kinyua, Ann W.; Ko, Chang Mann; Doan, Khanh V.; Yang, Dong Joo; Huynh, My Khanh Q.; Moh, Sang Hyun; Choi, Yun Hee; Kim, Ki Woo.

In: Experimental and Molecular Medicine, Vol. 50, No. 2, e437, 02.02.2018.

Research output: Contribution to journalArticle

TY - JOUR

T1 - 4-hydroxy-3-methoxycinnamic acid regulates orexigenic peptides and hepatic glucose homeostasis through phosphorylation of FoxO1

AU - Kinyua, Ann W.

AU - Ko, Chang Mann

AU - Doan, Khanh V.

AU - Yang, Dong Joo

AU - Huynh, My Khanh Q.

AU - Moh, Sang Hyun

AU - Choi, Yun Hee

AU - Kim, Ki Woo

PY - 2018/2/2

Y1 - 2018/2/2

N2 - 4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is known to have numerous beneficial health effects, including anti-obesity and anti-hyperglycemic properties. However, the molecular networks that modulate the beneficial FA-induced metabolic effects have not been well elucidated. In this study, we explored the molecular mechanisms mediating the beneficial metabolic effects of FA. In mice, FA protected against high-fat diet-induced weight gain, reduced food intake and exhibited an overall improved metabolic phenotype. The food intake suppression by FA was accompanied by a specific reduction in hypothalamic orexigenic neuropeptides, including agouti-related protein and neuropeptide Y, with no significant changes in the anorexigenic peptides pro-opiomelanocortin and cocaine and amphetamine-regulated transcript. FA treatment also inhibited fat accumulation in the liver and white adipose tissue and suppressed the expression of gluconeogenic genes, including phosphoenolpyruvate carboxylase and glucose-6-phosphatase. Furthermore, we show that FA phosphorylated and inactivated the transcription factor FoxO1, which positively regulates the expression of gluconeogenic and orexigenic genes, providing evidence that FA might exert its beneficial metabolic effects through inhibition of FoxO1 function in the periphery and the hypothalamus.

AB - 4-hydroxy-3-methoxycinnamic acid (ferulic acid, FA) is known to have numerous beneficial health effects, including anti-obesity and anti-hyperglycemic properties. However, the molecular networks that modulate the beneficial FA-induced metabolic effects have not been well elucidated. In this study, we explored the molecular mechanisms mediating the beneficial metabolic effects of FA. In mice, FA protected against high-fat diet-induced weight gain, reduced food intake and exhibited an overall improved metabolic phenotype. The food intake suppression by FA was accompanied by a specific reduction in hypothalamic orexigenic neuropeptides, including agouti-related protein and neuropeptide Y, with no significant changes in the anorexigenic peptides pro-opiomelanocortin and cocaine and amphetamine-regulated transcript. FA treatment also inhibited fat accumulation in the liver and white adipose tissue and suppressed the expression of gluconeogenic genes, including phosphoenolpyruvate carboxylase and glucose-6-phosphatase. Furthermore, we show that FA phosphorylated and inactivated the transcription factor FoxO1, which positively regulates the expression of gluconeogenic and orexigenic genes, providing evidence that FA might exert its beneficial metabolic effects through inhibition of FoxO1 function in the periphery and the hypothalamus.

UR - http://www.scopus.com/inward/record.url?scp=85041655575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041655575&partnerID=8YFLogxK

U2 - 10.1038/emm.2017.253

DO - 10.1038/emm.2017.253

M3 - Article

C2 - 29391540

AN - SCOPUS:85041655575

VL - 50

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 2

M1 - e437

ER -